



CureVac is a biopharmaceutical company pioneering the therapeutic application of messenger RNA (mRNA), opening up an entirely novel class of drugs.

The company has built a unique position in the field of research and therapeutic development of mRNA and has secured a related comprehensive IP portfolio.

CureVac has developed a set of proprietary technologies for the design and GMP-production of active mRNA molecules. Today, CureVac is focussing on the development of therapeutic and prophylactic vaccines as well as adjuvants. Two cancer vaccines, currently in Phase I / II clinical trials are being developed to treat prostate cancer and non-small cell lung cancer (NSCLC).

TECHNOLOGIES

CureVac has developed three technologies:

RNActive®

For the delivery of modified and formulated mRNA molecules for a broad range of therapeutic applications

RNAduvant®

For the use of mRNA as an immune stimulant

PUREmessenger®

For the GMP-production and purification of full-length mRNA



These unique technologies enable the Company to develop and manufacture mRNA molecules within a short timeframe, which produce active proteins when introduced into organisms. CureVac currently is focussing on immune-stimulating antigens, like certain tumour-associated and viral antigens.

MECHANISM OF ACTION

The Company's approach is based on the discovery that when modified, the direct application of mRNA via injection can lead to the expression of functional proteins. Until now, mRNA was regarded as being unsuitable for therapeutic applications because of its instability and difficult handling. CureVac's proprietary technologies overcome these obstacles and use mRNA effectively for various therapeutic applications.

In preclinical studies, the Company has already demonstrated that the injection of stabilized mRNA encoding for cancer and viral antigens can generate a broad and potent immune response.

ADVANTAGES

CureVac's approach has a number of advantages:

- **Versatile** – nearly all proteins can be displayed as endogenous proteins, prolonged bioavailability
- **Efficient** – as with vaccines: Effective activation of cellular and humoral immune response
- **Safe** – transient expression, no risk of genomic-integration and viral vector issues as with DNA compounds
- **Simple** – minimized non-replicating vectors, directly applied, combination feasible
- **Standardized** – universally applicable GMP-grade production processes for all constructs
- **Stable** – PUREmessenger® products can be stored at room temperature according to its formulation

DEVELOPMENT PIPELINE

	Research	Non-clinical Development	Phase I	Phase II	Phase III
RNActive®-derived mRNA					
Immunotherapy in Oncology					
Prostate Cancer – EU		CV9103			
Prostate Cancer – USA		CV9103			
Non-small Cell Lung Cancer		CV9201			
Prophylactic Vaccines					
Undisclosed					
RNAduvant®-derived RNA					
Undisclosed					

COMMERCIALIZATION STRATEGY

CureVac is actively seeking for strategic alliances and partnerships in order to fully exploit the potential of its technology platform and maturing product pipeline. The Company will consider in-licensing opportunities.



HISTORY

The Company was founded in December 2000 by Ingmar Hoerr, Florian von der Mülbe, Hans-Georg Rammensee, Steve Pascolo, and Günther Jung as a spin off from Tübingen University to develop and commercialize mRNA as a therapeutic. In 2003 CureVac closed a € 2.6 million Series A financing round, allowing the company to establish a GMP production unit. Since 2006, CureVac has raised an additional € 35 million in a second round of venture capital financing, enabling the Company to focus entirely on the research, development and production of mRNA-based therapeutics.



FOUNDED

2000

LOCATION

TÜBINGEN, GERMANY
(HEADQUARTERS)
FRANKFURT AM MAIN, GERMANY
(CLINICAL DEVELOPMENT)

MANAGEMENT

INGMAR HOERR, PhD, MBA (MANAGING DIRECTOR)
FLORIAN VON DER MÜLBE, PhD, MBA (COO)
KARL-JOSEF („KAJO“) KALLEN, MD, PHD (CSO)

NUMBER OF EMPLOYEES

63

FOCUS

mRNA BASED IMMUNOTHERAPY

INDICATIONS

PROSTATE CANCER
NON-SMALL CELL LUNG CANCER
PROPHYLACTIC VACCINE

PIPELINE

CLINICAL

FINANCING HISTORY

APPROX. € 38 MILLION
IN TWO PRIVATE EQUITY ROUNDS

INVESTORS

DIEVINI HOPP BIOTECH HOLDING GMBH&CO. KG

SUPERVISORY BOARD

FRIEDRICH VON BOHLEN, PHD (CHAIRMAN)
WOLFGANG HARTWIG, PHD
BERTHOLD WIPFLER
CORINNA MICKEL, LLD

SCIENTIFIC ADVISORY BOARD

JOHANNES VIEWEG, MD (CHAIRMAN)
WOLFGANG HARTWIG, PHD
ALEXANDER KNUTH, MD
GIORGIO PARMIANI, MD
HANS-GEORG RAMMENSEE, PHD
CAETANO REIS E SOUSA, DPHIL

More Information:

CureVac GmbH
Marijke Barner, PhD
Paul-Ehrlich-Str. 15
72076 Tübingen, Germany

T +49 (0)70 71.92 0 53 - 61
F +49 (0)70 71.92 0 53 - 11
communications@curevac.com

www.curevac.com